Advances in the Management of Gout


Program Dates: June 11, 2019 - June 10, 2020
Credits: 1.0 AMA PRA Category 1 Credit™; 1.0 CNE Contact Hour


Ankle painful - skeleton x-ray, 3D Illustration medical concept.

Advances in the Management of Gout

Program Overview

This CME/CNE program is derived from content presented at the Congress of Clinical Rheumatology 2019. The expert faculty will provide an overview of current and emerging therapies for the treatment of gout. This includes an analysis of lifestyle changes and pharmacological interventions as it relates to improving patient outcomes. The faculty will also discuss pathophysiology, prevention, accurate diagnosis, and imaging techniques, including pitfalls to providing optimal care. The information provided by the expert faculty will enable healthcare providers to optimally treat and manage their patients with gout.

Target Audience

Rheumatologists, physicians, internists, nurses, nurse practitioners, physician assistants, and other healthcare providers that are involved in the management of gout

Learning Objectives

1. Discuss the pathophysiology, prevention, accurate diagnosis, imaging, and therapeutic targets for gout and associated comorbidities
2. Review current clinical trial data for lifestyle and pharmacological interventions to manage patients with gout
3. Activate and educate the interprofessional team to deliver optimal care for patients with gout, including intravenous therapeutics

Faculty

 

#1 and #2 Epstein HeadshotAlan L. Epstein, MD
Clinical Professor of Medicine
University of Pennsylvania School of Medicine
Attending Physician, Pennsylvania Hospital
Philadelphia, Pennsylvania

 

#1 and #2 N. Lawerence EdwardsLawrence Edwards, MD
Professor of Medicine
Division of Rheumatology and Clinical Immunity
Program Director, Internal Medicine Residency
University of Florida
Gainesville, Florida

 

 

#1 Joan McTigueJoan McTigue, MS, PA-C
University of Florida
VA Medical Center
Gainesville, Florida

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

 

FacultyRelationship Identified With:
Alan L. Epstein, MD (Chair)Speaker’s Bureau: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Genentech Inc.; Janssen Pharmaceuticals, Inc.; Eli Lilly and Company; Merck & Co.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Quest Pharmaceuticals, Inc.; Regeneron; Sanofi-aventis U.S. LLC
N. Lawrence Edwards, MDConsultant/Advisor: Horizon Pharmaceuticals; Selecta Biosciences Inc.; Takeda Pharmaceutical Company 
Joan McTigue, MS, PA-CNothing to disclose


Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Screen Shot 2018-12-11 at 12.19.42 PM

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hours). Provider number P0491.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Horizon Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Horizon Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
8. 60 minutes of participation = 1 CNE contact hour

CE Inquiries/Special Needs

For all CME/CNE inquiries or special needs, please contact [email protected].

BUTTON

Provided by AcademicCME AcademicCME-web